Lataa...
The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer deaths. Erlotinib is the first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), the National Comprehensive Cancer Network (NCCN) guidelines recommend it as a first-line agent in patients with sensiti...
Tallennettuna:
| Julkaisussa: | Medicine (Baltimore) |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Wolters Kluwer Health
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4718287/ https://ncbi.nlm.nih.gov/pubmed/26765461 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000002495 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|